537 related articles for article (PubMed ID: 28665987)
1. Prions amplify through degradation of the VPS10P sorting receptor sortilin.
Uchiyama K; Tomita M; Yano M; Chida J; Hara H; Das NR; Nykjaer A; Sakaguchi S
PLoS Pathog; 2017 Jun; 13(6):e1006470. PubMed ID: 28665987
[TBL] [Abstract][Full Text] [Related]
2. Novel amplification mechanism of prions through disrupting sortilin-mediated trafficking.
Sakaguchi S; Uchiyama K
Prion; 2017 Nov; 11(6):398-404. PubMed ID: 29099278
[TBL] [Abstract][Full Text] [Related]
3. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity.
Vetrugno V; Cardinale A; Filesi I; Mattei S; Sy MS; Pocchiari M; Biocca S
Biochem Biophys Res Commun; 2005 Dec; 338(4):1791-7. PubMed ID: 16288721
[TBL] [Abstract][Full Text] [Related]
4. The multivesicular body is the major internal site of prion conversion.
Yim YI; Park BC; Yadavalli R; Zhao X; Eisenberg E; Greene LE
J Cell Sci; 2015 Apr; 128(7):1434-43. PubMed ID: 25663703
[TBL] [Abstract][Full Text] [Related]
5. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells.
Bate C; Tayebi M; Diomede L; Salmona M; Williams A
BMC Biol; 2008 Sep; 6():39. PubMed ID: 18789130
[TBL] [Abstract][Full Text] [Related]
6. Cofactor and glycosylation preferences for in vitro prion conversion are predominantly determined by strain conformation.
Burke CM; Walsh DJ; Mark KMK; Deleault NR; Nishina KA; Agrimi U; Di Bari MA; Supattapone S
PLoS Pathog; 2020 Apr; 16(4):e1008495. PubMed ID: 32294141
[TBL] [Abstract][Full Text] [Related]
7. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.
Bate C; Tayebi M; Williams A
BMC Biol; 2008 Feb; 6():8. PubMed ID: 18269734
[TBL] [Abstract][Full Text] [Related]
8. Folding and misfolding of the prion protein in the secretory pathway.
Tatzelt J; Winklhofer KF
Amyloid; 2004 Sep; 11(3):162-72. PubMed ID: 15523918
[TBL] [Abstract][Full Text] [Related]
9. 4-hydroxytamoxifen leads to PrPSc clearance by conveying both PrPC and PrPSc to lysosomes independently of autophagy.
Marzo L; Marijanovic Z; Browman D; Chamoun Z; Caputo A; Zurzolo C
J Cell Sci; 2013 Mar; 126(Pt 6):1345-54. PubMed ID: 23418355
[TBL] [Abstract][Full Text] [Related]
10. Prion infection impairs lysosomal degradation capacity by interfering with rab7 membrane attachment in neuronal cells.
Shim SY; Karri S; Law S; Schatzl HM; Gilch S
Sci Rep; 2016 Feb; 6():21658. PubMed ID: 26865414
[TBL] [Abstract][Full Text] [Related]
11. Abnormalities in stress proteins in prion diseases.
Tatzelt J; Voellmy R; Welch WJ
Cell Mol Neurobiol; 1998 Dec; 18(6):721-9. PubMed ID: 9876878
[TBL] [Abstract][Full Text] [Related]
12. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease.
Pan T; Wong P; Chang B; Li C; Li R; Kang SC; Wisniewski T; Sy MS
J Virol; 2005 Jan; 79(2):934-43. PubMed ID: 15613322
[TBL] [Abstract][Full Text] [Related]
13. Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation.
Alleaume-Butaux A; Nicot S; Pietri M; Baudry A; Dakowski C; Tixador P; Ardila-Osorio H; Haeberlé AM; Bailly Y; Peyrin JM; Launay JM; Kellermann O; Schneider B
PLoS Pathog; 2015 Aug; 11(8):e1005073. PubMed ID: 26241960
[TBL] [Abstract][Full Text] [Related]
14. A receptor for infectious and cellular prion protein.
Martins VR
Braz J Med Biol Res; 1999 Jul; 32(7):853-9. PubMed ID: 10454744
[TBL] [Abstract][Full Text] [Related]
15. Mouse-hamster chimeric prion protein (PrP) devoid of N-terminal residues 23-88 restores susceptibility to 22L prions, but not to RML prions in PrP-knockout mice.
Uchiyama K; Miyata H; Yano M; Yamaguchi Y; Imamura M; Muramatsu N; Das NR; Chida J; Hara H; Sakaguchi S
PLoS One; 2014; 9(10):e109737. PubMed ID: 25330286
[TBL] [Abstract][Full Text] [Related]
16. Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.
Cortez LM; Campeau J; Norman G; Kalayil M; Van der Merwe J; McKenzie D; Sim VL
J Virol; 2015 Aug; 89(15):7660-72. PubMed ID: 25972546
[TBL] [Abstract][Full Text] [Related]
17. The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication.
Bate C; Tayebi M; Williams A
Biochem J; 2010 Apr; 428(1):95-101. PubMed ID: 20196773
[TBL] [Abstract][Full Text] [Related]
18. Prion protein conversion in vitro.
Supattapone S
J Mol Med (Berl); 2004 Jun; 82(6):348-56. PubMed ID: 15014886
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-specific protease 14 modulates degradation of cellular prion protein.
Homma T; Ishibashi D; Nakagaki T; Fuse T; Mori T; Satoh K; Atarashi R; Nishida N
Sci Rep; 2015 Jun; 5():11028. PubMed ID: 26061634
[TBL] [Abstract][Full Text] [Related]
20. Molecular clues to pathogenesis in prion diseases.
Laurent M; Johannin G
Histol Histopathol; 1997 Apr; 12(2):583-94. PubMed ID: 9151145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
